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I.

INTRODUCTION

Biologic medicines are fundamentally different from
traditional “small molecule” therapies and therefore present new
challenges in designing the intellectual property architecture that
1
will protect them. Protecting the intellectual property (IP) of
†
Dr. Kristina M. Lybecker is an Associate Professor of Economics at
Colorado College in Colorado Springs, CO. BA, Macalester College; PhD,
University of California, Berkeley.
1. Biopharmaceuticals are currently produced using one of two technology
platforms and the active chemical substances can be classified as “large molecules”
or “small molecules.” Historically, pharmaceuticals have been small, chemically
manufactured molecules, and these molecules still comprise more than ninety
percent of drugs currently available. “Small molecule” therapies are synthesized by
chemical reactions between different organic and/or inorganic compounds. In
comparison, biologics or large molecules are therapeutic proteins and are most
often derived from living cells. See Small and Large Molecules: Drugs on a Chemical
and Biological Basis, BAYER HEALTHCARE, http://www.bayerpharma.com/en
/research-and-development/technologies/small-and-large-molecules/index.php
(last visited Mar. 25, 2014). Biologics are produced from micro-organisms or
animals by utilizing the metabolic processes of the organisms themselves. Biologics
include insulin, monoclonal antibodies, vaccines, blood and blood products,
protein hormones, cellular therapies, allergenic extracts, and gene therapy
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biologics is complicated, difficult, and essential to the future of
medicine. This new frontier is also one of the remaining hurdles in
the Trans-Pacific Partnership (TPP) Trade Agreement negotiations. The discussions currently center on a proposed twelve years
of data exclusivity for biologics and the consequences dataexclusivity will have for global public health and access to
medicines.
Data exclusivity is essential to the future of biologic medicines,
but the nuances of their production greatly complicate the logistics
of protecting their intellectual property. Data exclusivity protection
allows for a period of time following marketing approval during
which competing firms may not use the innovative firm’s safety and
efficacy data—from proprietary preclinical and clinical trial
results—to obtain marketing authorization for a generic version of
the drug. Beginning when the compound first shows medicinal
promise, the generation and compilation of this data is expensive
and time consuming. Data exclusivity provides the innovator firm
with a period of protection for its investment in clinical trials and
data collection, regardless of the length of time required to bring
the drug to market.
Although complementary, patents and data exclusivity
protection incentivize innovation in different ways and serve
distinct purposes. Patents protect inventions that meet the
standards of patentability and are novel, nonobvious, and useful.
They protect innovations ranging from breakthrough discoveries to
incremental improvements. Due to the length of the drugdevelopment and patent-approval processes, effective patent terms
rarely correspond to FDA approval, the result of which is that
innovative therapies may experience patent expiry shortly after
making it to market. In contrast, data exclusivity protects the
tremendous investments of time, talent, and financial resources
required to establish a new therapy as safe and effective. This is
accomplished by requiring competing firms seeking regulatory
approval of the same or a similar product to independently
generate the comprehensive preclinical and clinical trial data
rather than rely on or use the innovator’s data. Alternatively, the
competing firm may wait a set period of time before utilizing the

products. Examples of biologics include: Adalimumab (Humira), Trastuzumab
(Herceptin), Etanercept (Enbrel), Bevacizumab (Avastin), and Rituximab
(Rituxan).
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innovator’s prior approval in an abbreviated regulatory approval.
Data exclusivity is not an extension of patent rights, and it does not
preclude a third party from introducing a generic version of the
innovator’s therapy during the data exclusivity period, provided
that the innovator’s data is not used to secure marketing approval.
In essence, data exclusivity protection incentivizes biopharmaceutical firms to invest in establishing the safety and efficacy of
their product and prevents competitors from free riding on these
efforts for a limited period of time.
The Drug Price Competition and Patent Term Restoration Act
2
of 1984, commonly called the Hatch-Waxman Act, provided
innovative drug firms with a period of patent extension as well as a
period of data exclusivity, in the hopes of providing a return on
their investment and an incentive for future innovation. These
protections have been crucial to the development of the innovative
drugs and therapies that currently enhance and extend life. They
are even more critical to the future of the biopharmaceutical
industry and the development of medicines that are more targeted
and more complex.
In an analysis of the appropriate length of data exclusivity, a
financial model was utilized to determine how long the exclusivity
period must be to provide a typical pioneer biologic a positive
return on investment. Drawing on a representative portfolio of
pioneer biologics, the break-even period ranges from thirteen to
3
sixteen years. An appropriate period of protection is essential if
the promise of biologics is to come to fruition. Beyond the
importance of biologics to public health and longevity, innovation
is crucial to trade and economic prosperity. As evidence of the
importance of these sectors, in 2011 IP-intensive industries
exported more than $1 trillion in goods and services, which
accounted for approximately seventy-four percent of total 2011
4
U.S. exports. Moreover, the biopharmaceutical industry is a
significant contributor. The biopharmaceutical industry of the
United States is the fourth-largest U.S. exporter among IP-intensive

2. Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as
amended in scattered sections of 21 and 35 U.S.C.).
3. Henry Grabowski et al., From the Analyst’s Couch: Data Exclusivity for
Biologics, 10 NATURE REVIEWS: DRUG DISCOVERY 15, 15–25 (2011).
4. IP Creates Jobs for America, GLOBAL INTELL. PROP. CENTER (May 25, 2012),
http://www.theglobalipcenter.com/ip-creates-jobs-america.
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industries, with exports valued at $49.4 billion in 2010.
Accordingly, the TPP Trade Agreement should include the
proposed twelve years of data exclusivity and provide innovative
firms with the incentives needed to continue to invest in the
breakthrough therapies that will extend and enhance life for years
to come.
II. BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT
The pharmaceutical industry is distinguished from other
knowledge-intensive industries in some very important ways. It is
uniquely set apart by the manufacture of a social good
characterized by high fixed costs, substantial informational and
regulatory costs, and relatively low marginal costs of production.
The apparatus embodied in the patent system encourages
additional pharmaceutical research and development (R&D) by
guaranteeing innovators a period of exclusivity during which they
are able to recover their R&D investments.
The intellectual property rights protection is of particular
importance to biopharmaceutical innovators, given that without
these measures innovators would have little incentive to invest in
new technologies that suffer from several market failures. The
production of knowledge––as embodied in biopharmaceutical
6
therapies––is characterized by the three sources of market failure.
First, information has one of the classic properties of public goods
and the externalities inherent to them: once discovered, knowledge
is both nonrival and nonexcludable. The cost of R&D is primarily a
fixed cost, while the marginal cost of production is very low. For
biopharmaceutical innovators, new technologies are easily copied
and sold by their competitors. Given the inherent challenges in
delineating and enforcing property rights to new technologies, it is
difficult for innovative firms to appropriate the returns accruing
from their investments. Accordingly, these investments may not be
made and pharmaceutical R&D would be under-produced.

5. ECON. & STATISTICS ADMIN. & U.S. PATENT & TRADEMARK OFFICE,
INTELLECTUAL PROPERTY AND THE U.S. ECONOMY (2012), available at http://www
.uspto.gov/news/publications/IP_Report_March_2012.pdf.
6. Kenneth Arrow, Economic Welfare and the Allocation of Resources for Invention,
in THE RATE AND DIRECTION OF INVENTIVE ACTIVITY: ECONOMIC AND SOCIAL FACTORS
609, 609–26 (Univs.-Nat’l Bureau ed., 1962).
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Second, another source of market failure stems from the
indivisibility of new knowledge. That is, its propensity to be discrete
rather than continuous in nature. This frequently results in
economies of scale and scope in the production of new knowledge.
In the biopharmaceutical industry, the R&D required for the
discovery of a new therapy is characterized by a large fixed cost.
Finally, the third source of market failure emanates from the
degree of risk and uncertainty inherent in the production of new
knowledge.
The presence of these market failures decreases the
probability that the rate of investment in the development and
diffusion of such technology will occur at the socially optimal level.
Given this, the remedy is to implement policies focused on
encouraging the development and diffusion of these technologies.
Intellectual property rights protection provides the market
exclusivity that incentivizes firms to invest in the difficult and
expensive R&D necessary for pharmaceutical advances. This
incentive system is the heart of the static/dynamic trade-off that
characterizes the existing patent system. In exchange for temporary
monopoly power (twenty years under the existing patent system), a
static loss, new knowledge is forever brought into the public
domain, a dynamic gain.
The protection afforded innovators under the patent system is
all the more important for the pharmaceutical industry due to the
tremendous costs of bringing a new medicine to market. Current
estimates place the fixed costs of drug development at close to
$1.2 billion. Granted, this is a highly controversial number, but
even if the cost is half that amount, it remains a significant
investment. The development of new drugs also requires a great
deal of time. On the road to approval by the Food and Drug
Administration (FDA), 5000 to 10,000 experimental compounds
are considered and after a period of ten to fifteen years typically
only one gains approval. Moreover, the few successes must make up
for the many failures, because only three out of every ten medicines
will recoup the money spent on their development. And at the
same time, the uniqueness of their product is threatened by the
fact it is very easy to copy. Innovator firms lose out if nobody else
has to bear the development cost and can still sell the drugs.
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III. THE HATCH-WAXMAN ACT AND TRADITIONAL “SMALL
MOLECULES”
As described elsewhere in this Issue on the thirtieth
anniversary of the Hatch-Waxman Act, the pharmaceutical industry
is characterized by high fixed costs of production and marketing
7
and relatively low marginal costs of production. While innovator
firms are required to invest significant resources and bear
substantial risk, generic producers must neither invest in the R&D
of these medicines nor risk a production failure. The HatchWaxman Act provides a tradeoff that allows innovator firms and
generic producers to share the market. The Act facilitates generic
production while maintaining the necessary financial incentives for
R&D by the innovators. Fundamentally, generic producers are able
to submit evidence of bioequivalence in place of independent
clinical data, resulting in tremendous cost savings. This is
complemented by a period of additional marketing exclusivity for
innovator firms, in order to partially compensate them for the
patent life lost to clinical testing and regulatory approval.
Importantly, this extension is in addition to the twenty years of
exclusivity granted by the issuance of a patent and it cannot exceed
8
five years. This tradeoff rewards generic producers with lower
costs, innovator firms with additional exclusivity, and consumers
with competition and lower drug prices following patent expiry.
The result is arguably economically efficient for several
reasons. First, through the bioequivalence provision, the HatchWaxman Act eliminates redundant clinical testing and the
associated expenditures. In addition, competition necessitates
more efficient production, lower costs, and savings, all of which are
passed on to patients. This has created a robust, successful U.S.
generic industry, and seventy-five percent of all prescriptions
dispensed are now generics.
IV. BIOLOGIC MEDICINES
Having acquired some understanding of the biopharmaceutical R&D process, as well as the role of patents in protecting
7. See Robert A. Armitage, The Hatch-Waxman Act: A Path Forward for Making It
More Modern, 40 WM. MITCHELL L. REV. 1200, 1219–23 (2014).
8. See 35 U.S.C. § 156 (2006); see also WENDY H. SCHACHT & JOHN R. THOMAS,
CONG. RESEARCH SERV., RS21129, PHARMACEUTICAL PATENT TERM EXTENSIONS 2
(2002).
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“small molecules,” it is important to establish why and in what ways
biologics differ. The first important distinction between “small
molecules” and biologics is based in their chemical structures. The
chemical structures of traditional “small molecule” pharmaceuticals
are commonly well defined. Given this, laboratory analysis is
generally able to determine all of the components, and replication
(generic production) is quite straightforward. Alternatively,
biologics are very difficult and sometimes impossible to
characterize scientifically due to the complexity of their chemical
structure. Perhaps surprisingly, a number of the components of a
9
finished biologic may be unknown. For obvious reasons this greatly
complicates the production of “generic” versions. Accordingly, the
FDA has struggled to establish “interchangeability” for complex
proteins. In contrast to conventional “small molecule” drugs for
which a generic drug can be chemically established to be the same
as an innovator drug, a biosimilar is a molecule that is similar but
not identical to the pioneer biologic.
A biologic is commonly defined as “a large molecule typically
derived from living cells and used in the treatment, diagnosis or
prevention of disease. Biologic medicines include therapeutic
proteins, DNA vaccines, monoclonal antibodies, and fusion
10
proteins.” In addition, the majority of biologics are produced
using recombinant DNA technology and are made by genetically
engineering living cells to produce the required proteins (rather
than through chemical synthesis). As a result, biologics are
considerably larger than “small molecule” drugs, often 200 to 1000
times their size and significantly more complex structurally.
Consequently, biologics are much more sensitive to even minute
changes in the manufacturing process. Due to both the size and
sensitivity of biologics, these medicines are most frequently
administered through an injection or infusion into a patient’s
body.
Biologics are therefore more difficult to characterize and to
produce such that even minor differences in production processes
or cell lines can generate variations in the resulting protein. As a
consequence, quality control is all the more important, and
production complications are potentially more catastrophic.
9. How Do Drugs and Biologics Differ?, BIOTECHNOLOGY INDUSTRY ORG. (Nov.
10, 2010), http://www.bio.org/articles/how-do-drugs-and-biologics-differ.
10. Biologics and Biosimilars: An Overview, AMGEN 12 (2012), http://www
.amgen.com/pdfs/misc/Biologics_and_Biosimilars_Overview.pdf .
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Several recent examples starkly illustrate this possibility. Consider
the 500 cases of fungal meningitis linked to contaminated
injectable corticosteroids formulated by the New England
Compounding Center in October 2012, and the 150 deaths
11
resulting from tainted Chinese heparin in 2008. Unfortunately,
immunogenicity problems may even result from small changes
made by the innovator company under controlled conditions. Note
the case of EPREX as described by the Biotechnology Industry
Organization:
Immunogenicity is an important concern regarding
the safety of biologics. This occurs when our bodies treat a
protein as if it is a foreign substance and try to attack the
protein with antibodies. Unlike chemical drugs, all
biologics have the potential to stimulate antibody
production in patients and such responses are highly
unpredictable. Sometimes the antibodies produced in
response to a biologic have no effect. Other times they
bind and inactivate the biologic, causing disease
progression. In still other cases, they can bind to and
inactivate a patient’s naturally occurring protein, which
means that the patient may be left with no options other
than regular blood transfusions.
One example of immunogenicity occurred a few years
ago when, at the request of the European Health
Authorities, Johnson & Johnson made a change in the
manufacturing process for its EPREX product––a product
that had been marketed for a decade with no evidence of
immunogenicity problems. The change caused a serious
adverse reaction in a small number of patients. These
patients lost their ability to make red blood cells because
they produced an antibody (triggered by the EPREX) that
inactivated both the administered protein (EPREX) and
the body’s natural protein that is essential for red blood
cell production. Johnson & Johnson eventually was able to
determine the cause of this adverse reaction and correct
it, but only after a very lengthy and expensive
investigation.
The EPREX case shows that one protein can be
different from another in ways that cannot be detected in
the laboratory, but are seen only by the body’s exquisitely
11. Larry Greenmeier, Heparin Scare: Deaths from Tainted Blood-Thinner Spur
Race for Safe Replacement, SCI. AM. (Nov. 4, 2008), http://www.scientificamerican
.com/article/heparin-scare-deaths/.
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sensitive immune system. If one change to a wellestablished complex manufacturing process, made by the
manufacturer who has intimate knowledge of the process,
can cause a problem with immunogenicity, surely the risk
is even greater with an entirely new manufacturer and
12
process––as will be the case with follow-on biologics.
Given that a minute change in the production process, raw
materials, temperature, pH, or cell line can result in a significant
alteration in the medicine’s quality, efficacy, or safety, the
interchangeability and substitutability of these products must be
approached with extreme caution. This is all the more critical given
the increasing importance and prevalence of biologics in the
pipeline of the biopharmaceutical industry. To date, approximately
200 biologic therapies have transformed the lives of more than
13
800 million patients. Moreover, by 2017 analysts believe that
biologics will comprise seven of the top ten global pharmaceuticals,
and that thirty percent of the pharmaceutical industry pipeline will
14
be biologics.
The distinctions that separate “small molecules” from biologic
medicines also generate very different economic outcomes in the
context of generic/biosimilar production. In the case of “small
molecules,” the emergence of a successful generic industry has
created competition through which prices have dropped
dramatically. Much of the debate surrounding data exclusivity for
biologics centers on the mistaken belief that prices would similarly
drop with the development of biosimilar competition. Accordingly,
the fear is that data exclusivity protection will lock in high prices
for biologic drugs. This argument was precisely the focus of a
recent letter from the AARP to U.S. Trade Representative Michael
15
Froman. Unfortunately, the cost savings achieved with generic
production and competition among “small molecule” drugs is
12. Why Is Patient Safety a Concern in the Biosimilars Debate?, BIOTECHNOLOGY
INDUSTRY ORG. (Nov. 10, 2010), http://www.bio.org/articles/why-patient-safety
-concern-biosimilars-debate.
13. BIOTECHNOLOGY INDUS. ORG., GUIDE TO BIOTECHNOLOGY 2008, at 84
(2008), available at http://www.bio.org/sites/default/files/BiotechGuide2008.pdf.
14. Why Biologics Matter: Biologics Contributing to Rising Healthcare Costs,
SANDOZ BIOPHARMACEUTICALS, http://www.sandoz-biosimilars.com/biosimilars2
/why_biologics_matter.shtml# (last visited March 25, 2014).
15. Ben Goad, AARP Warns Trade Deal Could Lock in High Drug Prices, THE HILL
(Oct. 23, 2013, 7:29 PM), http://thehill.com/blogs/regwatch/healthcare/330199
-trade-agreement-could-lock-in-high-drug-prices-aarp-warns.
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unlikely to be available through biosimilars. For conventional
“small molecule” drugs, over the necessary three to five years for
development of a generic, the cost is approximately one to five
16
million dollars, resulting in a lower-cost alternative for patients. In
contrast, the majority of shortcuts available to generic
17
manufacturers will not be available to biosimilar producers.
Industry experts expect biosimilar firms to need to invest in clinical
trials as well as manufacturing and post-approval safety monitoring
programs similar to those of the innovative biologic company.
Accordingly, biosimilar products will likely require eight to ten
18
years to develop, at a cost of $75–250 million. Current studies
place the cost savings from biosimilar production at between ten
and twenty percent less than the cost of the pioneer biologic. The
European experience provides data showing that biosimilars offer
19
just a ten percent discount from the brand.
V. WHY PATENTS AREN’T ENOUGH
Patents protect traditional “small molecule” drugs for a twentyyear term. However, biologic therapies are more challenging to
comprehensively protect with patents due to their complexity, size,
20
and the large number of similar effective variants. As described
above, comprehensive protection is critical to the future
16. While innovator firms bear the entire cost of pharmaceutical research
and development, including the costs of all of the molecules that fail, generic
producers must only reverse engineer the innovative drug and establish its
bioequivalence. This translates into significantly lower development costs for
generic producers.
17. See CONG. BUDGET OFFICE, COST ESTIMATE: S. 1695 BIOLOGICS PRICE
COMPETITION AND INNOVATION ACT OF 2007 (2008), available at http://www.cbo.gov
/ftpdocs/94xx/doc9496/s1695.pdf.
18. Biologics and Biosimilars: An Overview, supra note 10, at 12; The European
Biosimilars Market: Trends and Key Success Factors, SCICASTS (Oct. 27, 2008),
http://scicasts.com/subscribe/9-special-reports/bio-it-a-biotechnology/2152-the
-european-biosimilars-market-trends-and-key-success-factors.
19. Peyton Howell, How Much Cheaper Will Biosimilars Be?, FIERCEPHARMA
(Mar. 2, 2012), http://www.fiercepharma.com/story/how-much-cheaper-will
-biosimilars-be/2012-03-02.
20. Jonathan Stroud, Power Without a Patent: Twelve-Year Biologics Data
Exclusivity Period and a Totality-of-the-Evidence Standard for Biosimilarity, OMICS GRP.
http://www.omicsgroup.com/conferences/ACS/conference/download-pdf.php
?file=7593-Speaker-Pdf-T.pdf (last visited Apr. 16, 2014) (abstract of presentation
at Second International Conference and Exhibition on Biowaivers and
Biosimilars).
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production of biologics due to the investment and risk associated
with their discovery and manufacture. Recent studies estimate that
the preapproval cost of developing a biologic approaches
$1.2 billion and that the time needed to recover the preapproval
21
R&D costs is between 12.9 and 16.2 years. This shaves vital years
off the effective patent life of these medicines. In the United States,
the Biologics Price Competition and Innovation Act of 2009
(“Biologics Act”) provides for twelve years of exclusivity for biologic
22
medicines. With its passage, Congress endeavored to fill the void
left by other forms of intellectual property rights in the protection
of biologics, specifically patents and trade secrets. While the period
of data protection for “small molecule” drugs is five years, the
length of this exclusivity is less important because generic drugs are
required to contain the identical active ingredient. That said, an
accompanying article in this journal makes an excellent case for
extending the length of exclusivity granted to certain “small
23
molecule” drugs for unmet medical needs. Nevertheless, in the
case of biosimilars, an identical active ingredient is not necessary;
similar effective variants are sufficient. Put simply, the regulatory
approval process does not require identity with the pioneer
biologic product it references, hence the source of the potential
patent protection gap.
Given this, without an extended period of data exclusivity
protection, a competing firm would be able to elude the
innovator’s patent (since its compound is adequately different)
while relying on the innovator’s data for regulatory approval. The
industry argues that this potential is exacerbated by two issues:
First, because of the nature of biologic products—large
molecules produced by living cells and organisms through
highly specific processes—patent protection is often
narrower than that of small molecule drugs. Second, the
creation of an abbreviated pathway for approval of similar

21. Joseph A. DiMasi & Henry G. Grabowski, The Costs of Biopharmaceutical
R&D: Is Biotech Different?, 28 MANAGERIAL & DECISION ECON. 469, 476 (2007);
Grabowski et al., supra note 3, at 15–25.
22. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 70017003, 124 Stat. 119 (2010) (codified in scattered sections of title 28, 29, 35, and
42 U.S.C.) (enacting Biologics Price Competition and Innovation Act of 2009,
H.R. 3590, 111th Cong. (2010)).
23. Armitage, supra note 7, at 1250–57.
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biological products creates new and strong incentives for
24
competitors to exploit this patent protection gap.
It is important to recognize that while patent protection and data
exclusivity may be considered complementary forms of protection,
they serve distinct purposes. Patents protect innovations that meet
the patentability standards and are thus novel, nonobvious, and
useful, covering both breakthrough advances and incremental
improvements. On the other hand, data protection incentivizes the
costly and time-consuming development work, which is required to
establish safety and efficacy and to secure regulatory approval of a
new product. This complementary protection necessitates that
biosimilar manufacturers independently conduct the comprehensive preclinical and clinical trials for their own product, or wait
the twelve years specified by the Biologics Act before requesting a
regulatory shortcut to approval based on the innovator’s prior
approval and data. This protection both safeguards the innovator’s
investments while also ensuring patient safety, especially given the
25
sensitivity and complexity of biologic medicines.
The growing importance of biologic medicines draws the
attention of generic producers, policymakers, public health
advocates, and patient groups. Costs are significant and potential
competition is of great interest to all parties. However, there are
important distinctions between the production of “small molecule”
generics and biosimilars. As noted above, biosimilar producers are
not required to demonstrate that their products contain the
identical active ingredient. Given this, biosimilars are exactly that,
similar, but not identical generic versions of pioneer biologics. As
such, the framework established by the Hatch-Waxman Act will not
apply in the same way to biosimilars. If independent,
comprehensive preclinical and clinical trials are required of
biosimilar manufacturers, the industry tradeoff will not apply.
Moreover, the cost savings generated by generic competition in
“small molecule” markets will probably not materialize in biosimilar
markets. The economic efficiencies generated by the HatchWaxman Act in the market for “small molecules” will not be
present in the markets for biologic medicines.
24. The Trans-Pacific Partnership and Innovation in the Bioeconomy: The Need
for 12 Years of Data Protection for Biologics, BIOTECHNOLOGY INDUSTRY ORG. 4
(July 18, 2013), http://www.bio.org/sites/default/files/TPP%20White%20Paper
%20_2_.pdf.
25. See generally id.
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VI. THE IMPORTANCE OF DATA EXCLUSIVITY PROTECTIONS
Data exclusivity protection is vital to the development of future
biologics and the preservation of the incentives needed to
encourage investment in the R&D that makes these drugs a reality.
As described above, recent studies estimate that the pre-approval
cost of developing a biologic approaches $1.2 billion and that the
time needed to recover the pre-approval R&D costs is between 12.9
26
and 16.2 years. The remaining effective patent life provides
innovators with their only opportunity to appropriate the returns
on their investments. The profitability of this limited period
determines whether or not future investments will be made.
Undermining the future of this technology with weakened
intellectual property protection for the limited cost savings
anticipated through biosimilar competition is undeniably short
sighted. The incentives to invest in biologic vaccines and therapies
must be preserved with twelve years of data exclusivity.
Accordingly, the current negotiations surrounding the TPP
Trade Agreement include provisions for twelve years of data
exclusivity for biologics. The TTP Trade Agreement is presently
under negotiation by the United States and eleven other countries:
Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia,
27
Mexico, New Zealand, Peru, Singapore, and Vietnam. The
agreement will promote trade and investment among member
countries as well as encourage economic growth and development,
innovation, and job creation. Given the importance and size of the
economies of the participating nations and their share of global
trade, the TPP Trade Agreement is among the most significant of
recent trade agreements. Specifically, the eleven other TPP
countries have a combined population of 482 million and generate
28
close to fifteen percent of global trade. In combination, the
current TPP countries represent the largest U.S. market for exports
of goods and services. In 2012, TPP countries consumed forty-five

26. DiMasi & Grabowski, supra note 21, at 470; Grabowski et al., supra note 3,
at 15–25.
27. Press Release, Office of the U.S. Trade Representative, Statement of the
Ministers and Heads of Delegation for the Trans-Pacific P’ship Countries (Dec. 10,
2013), http://www.ustr.gov/tpp.
28. BUS. ROUNDTABLE, THE TRANS-PACIFIC PARTNERSHIP AGREEMENT: AN
OPPORTUNITY FOR AMERICA 1 (2013), available at http://businessroundtable.org
/studies-reports/downloads/TPP_Summary_Oct_2013.pdf.
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percent of exported U.S. goods. The agreement seeks to eliminate
all trade tariffs; promote free trade; and comprehensively addresses
trade in goods and services, rules of origin, trade remedies, nontariff barriers to trade, intellectual property, competition policy,
and government procurement policy. The negotiations are
ongoing, but a number of sticking points have greatly slowed their
progress. Specific issues include policies surrounding investment,
the environment and climate change, e-commerce, public
procurement, agricultural export subsidies, and intellectual
property rights.
For the biopharmaceutical industry, a global standard of
protection is essential to ensure the innovator firm receives a
return on its investment, as well as for ensuring the safety and
efficacy of these medicines. Moreover, trade and IP protection
enhance growth, and growth furthers access to medicines. A 2006
United Nations Industrial Development Organization report
studied the role of intellectual property rights in technology
transfer and economic growth in advanced nations, concluding
that evidence suggests that strengthening intellectual property
rights raises growth, in part due to increased innovation and
technology diffusion. In addition, for middle-income countries,
data indicate that stronger intellectual property rights regimes
facilitate both domestic innovation and technology diffusion
through foreign patenting and international trade, which can
30
positively impact growth. A 2012 study further supports these
conclusions, finding that “patent protection enhances innovation
and economic growth, in countries where the capacity to conduct
31
innovative [R&D] exists.” Intellectual property rights encourage
growth, and growth enhances access. History supports this
argument as well. The strength of these linkages is evident in the
recent experiences of China, India, and Brazil. In the ten-year

29. Id. at 2.
30. Rod Falvey et al., The Role of Intellectual Property Rights in Technology Transfer
and Economic Growth: Theory and Evidence (United Nations Indus. Dev. Org.,
Working Paper, 2006), available at http://www.unido.org/fileadmin/user_media
/Publications/Research_and_statistics/Branch_publications/Research_and
_Policy/Files/Working_Papers/2006/WPjuly2006%20IPR_rights_in_technology
_transfer.pdf.
31. Yee Kyoung Kim et al., Appropriate Intellectual Property Protection and
Economic Growth in Countries at Different Levels of Development, 41 RES. POL’Y 358, 358
(2012).
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period between 1995 and 2005, these three nations doubled or
32
nearly doubled their Patent Rights Index rating. Significantly, in
the same period both biotechnology patenting and technology
transfer, as captured by Foreign Direct Investment, increased
33
substantially. These studies all point to the importance of
encouraging innovation, supporting intellectual property
protection, and including data exclusivity protections for
development and growth.
VII. CONCLUSION
History has repeatedly shown that technology evolves faster
than the legal architecture that surrounds it. The provision of data
exclusivity protections is a straightforward legal step to catch up to
the science that brings us biologic medicines. Biologic medicines
are critical to the healthcare advances of the future, and data
exclusivity is vital to innovative biologics. The period of data
exclusivity provides innovators with an incentive to invest in the
testing data necessary to prove a drug’s safety and efficacy by
granting them a measure of certainty that they will enjoy a fixed
amount of time during which they maintain proprietary control of
the test data that resulted in the approval of its drug, before
requiring that data be made available to generic imitators. Data
exclusivity protection is crucial to biopharmaceutical innovation,
and this innovation is crucial to the future of healthcare, trade, and
economic prosperity. As technology changes to enable the
development of new biologic vaccines and therapies, intellectual
property protection must also evolve to ensure protection for these
products. If we believe in the importance of biologic medicines for
the future of healthcare, we must protect them with twelve years of

32. MEIR PEREZ PUGATCH ET AL., TAKING STOCK: HOW GLOBAL BIOTECHNOLOGY
BENEFITS FROM INTELLECTUAL PROPERTY RIGHTS 45 (2012). The Property Rights
Index is arguably the most reputable and widely accepted criterion used to
measure the cross-national strength of intellectual property rights. As calculated
by Park, the index measures the cross-national strength of patent rights in
122 nations between 1960 to 2005. The index ranges from zero, which indicates
the weakest level of protection, to five, indicating the highest. Five categories of
patent law are utilized to codify the index: extent of coverage, membership in
international patent agreements, duration of protection, enforcement provisions,
and restrictions on patent rights. Walter G. Park, International Patent Protection:
1960–2005, 37 RES. POL’Y 761, 761 (2008).
33. PUGATCH ET AL., supra note 32, at 45.
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data exclusivity. This time is essential for incentivizing investments
in these technologies and rewarding the innovators who are willing
to take these risks.
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